Volume 24 Number 9| September 2018| Dermatology Online Journal || Review 24(9): 1 Infantile hemangiomas: our current understanding and treatment options Yssra S Soliman1 BA, Amor Khachemoune2,3 MD Affiliations: 1Albert Einstein College of Medicine, Bronx, New York, USA, 2State University of New York Downstate, Department of Dermatology, Brooklyn, New York, USA 3Veterans Health Administration, Department of Dermatology, Brooklyn, New York, USA Corresponding Author: Amor Khachemoune MD, FAAD, FACMS, Veterans Affairs Hospital & SUNY Downstate, Dermatology Service, 800 Poly Place, Brooklyn, NY 11209, Tel: 718-630-3725, Fax: 718-630-2881, Email:
[email protected] or in visceral organs. Classically, the hemangiomas Abstract display rapid growth during the third month of life, Infantile hemangioma (IH) is the most common followed by slow involution [4]. By 48 months, vascular tumor of infancy, affecting up to 10% of all approximately 90% of cases will have regressed [5]. infants. Our understanding of IH and its management has greatly evolved. The etiology of IH is unclear but This article aims to review the epidemiology, clinical hypoxia is thought to play a key role. Furthermore, presentation, genetics, histopathology, associated GLUT1, IGF2, and HIF-1- syndromes, evolution without treatment, and important mediators. Current management options treatment options of infantile hemangioma. The include active observation, medical treatment, and primary database used was PubMed. We searched surgical intervention. The goals of treatment are , preventing cosmetic disfiguration, psychosocial , distress, and life-threatening complications. Infantile hemangioma should be managed with an individual, f patient-centered approach. Generally, uncompli- -1- cated IH can be observed up to 18 months. However, IH should be treated in the setting of bleeding, Historical note and evolving classification ulceration, functional compromise, or eventual Infantile hemangioma has been reported in the failure to regress.